Company: BIAF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001840
Chunk: 303

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1B
Chunk 303
---
, if
any, to fund the development and expansion of our business, and we do not anticipate declaring or paying any cash dividends in the foreseeable
future. Any future determination regarding the declaration and payment of dividends, if any, will be at the discretion of our Board of
Directors and will depend on then-existing conditions, including our financial condition, results of operations, contractual restrictions,
capital requirements, business prospects, and other factors our Board of Directors may deem relevant.

Unregistered
Sales of Equity Securities

We
did not sell any equity securities during the quarter ended December 31, 2024, in transactions that were not registered under the Securities
Act other than as previously disclosed in our filings with the SEC.

Securities
Authorized for Issuance Under Equity Compensation Plans

The
following table presents information as of December 31, 2024, with respect to shares of our Common Stock that may be issued under our equity incentive plans.

    Plan category 
    Number of securities to be issued upon exercise of outstanding options, warrants, and rights  
    Weighted-average exercise price of outstanding options, warrants, and rights  
    Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) 

    (a)  
    (b)  
    (c) 
  
    Equity compensation plans approved by security holders  

    2024 Equity Incentive Plan 
     519,792  
    $2.00  
     1,480,208 
  
    2014 Equity
Incentive Plan 
     380,132  
    $5.78  
     — 
  
    Equity compensation plans not approved by security holders 
     —  
     —  
     — 
  
    Total 
     899,924  
    $3.59  
     1,480,208 

Item
6. [Reserved.]

Item
7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

This
section presents management’s perspective on our financial condition and results of operations. The following discussion and analysis
(the “MD&A”) is intended to highlight and supplement data and information presented elsewhere in this Annual Report.
The MD&A is also intended to provide you with information that will assist you in understanding our consolidated financial statements,
the changes in key items in those consolidated financial statements from year to year, and the primary factors that accounted for those
changes